Berberine in the Treatment of Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis

Table 1

Characteristics of included trials (two-armed parallel group).

Author	Number of patients		Intervention
	Experimental	Control	Experimental	Control	Duration (wks)	Outcomes
Liu and Hu 2008 [12]	30	30	LM, Ber, Met	LM + Met	8	FBG, PPG, HbA1c, FINS
Li 2008 [32]	33	32	LM, Ber	LM + Met	12	FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C
Wang 2008 [14]	30	31	LM, Ber	LM	12	FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C, AE
Zhang et al. 2008 [9]	58	52	LM, Ber	Placebo, LM	12	FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C, AE
Yin et al. 2008 [10]	15	16	LM, Ber	Met, LM	13	FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C, AE
Sheng and Xie 2010 [15]	30	30	Ber, Met, Glip	Met, Glip	12	FBG, FINS, AE
Ye 2010 [16]	40	40	Ber, Met, Glim	Met, Glim	12	FBG, PPG, HbA1c, TC, TG, LDL-C, HDL-C, AE
Zhang et al. 2011 [17]	30	30	LM, Ber	LM, Ber, Ros	12	FBG, HbA1c, TC, TG, LDL-C, HDL-C
Yin et al. 2011 [18]	30	30	LM, Ber, Met	LM, Met	24	FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C, AE

Note: AE: adverse effect; Ber: berberine; Glim: glimepiride; Glip: glipizide; LM: lifestyle modification; Met: metformin; Ros: rosiglitazone.